DK2123276T3 - Farmaceutisk sammensætning omfattende pyrazinderivat og fremgangsmåde til anvendelse af et pyraziderivat i kombination - Google Patents

Farmaceutisk sammensætning omfattende pyrazinderivat og fremgangsmåde til anvendelse af et pyraziderivat i kombination

Info

Publication number
DK2123276T3
DK2123276T3 DK08711267.8T DK08711267T DK2123276T3 DK 2123276 T3 DK2123276 T3 DK 2123276T3 DK 08711267 T DK08711267 T DK 08711267T DK 2123276 T3 DK2123276 T3 DK 2123276T3
Authority
DK
Denmark
Prior art keywords
derivative
pyrazide
procedure
combination
pharmaceutical composition
Prior art date
Application number
DK08711267.8T
Other languages
English (en)
Inventor
Masako Maekawa
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Application granted granted Critical
Publication of DK2123276T3 publication Critical patent/DK2123276T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK08711267.8T 2007-02-16 2008-02-14 Farmaceutisk sammensætning omfattende pyrazinderivat og fremgangsmåde til anvendelse af et pyraziderivat i kombination DK2123276T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007035975 2007-02-16
PCT/JP2008/052425 WO2008099874A1 (ja) 2007-02-16 2008-02-14 ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法

Publications (1)

Publication Number Publication Date
DK2123276T3 true DK2123276T3 (da) 2013-01-02

Family

ID=39690101

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08711267.8T DK2123276T3 (da) 2007-02-16 2008-02-14 Farmaceutisk sammensætning omfattende pyrazinderivat og fremgangsmåde til anvendelse af et pyraziderivat i kombination

Country Status (21)

Country Link
US (1) US8759354B2 (da)
EP (1) EP2123276B1 (da)
JP (1) JP5255456B2 (da)
KR (1) KR101479083B1 (da)
CN (1) CN101610772B (da)
AU (1) AU2008215397B2 (da)
BR (1) BRPI0807597B8 (da)
CA (1) CA2677905C (da)
CY (1) CY1113435T1 (da)
DK (1) DK2123276T3 (da)
ES (1) ES2396595T3 (da)
HR (1) HRP20130111T1 (da)
IL (1) IL200285A (da)
MX (1) MX2009008779A (da)
NZ (1) NZ578989A (da)
PL (1) PL2123276T3 (da)
PT (1) PT2123276E (da)
RU (1) RU2463051C2 (da)
SI (1) SI2123276T1 (da)
WO (1) WO2008099874A1 (da)
ZA (1) ZA200905536B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117114A1 (en) * 2009-04-09 2010-10-14 Lg Electronics Inc. Display apparatus
DK2568976T3 (da) * 2010-05-10 2016-01-11 Academia Sinica Zanamivir-phosphonat-kongener med anti-influenzaaktivitet og fastlæggelse af oseltamivir-følsomhed hos influenzavira
US20130217708A1 (en) 2010-09-30 2013-08-22 Toyama Chemical Co., Ltd. Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
RS54408B1 (sr) 2010-09-30 2016-04-28 Toyama Chemical Co. Ltd. Natrijumova so 6-fluor-3-hidroksi-2-pirazin karboksamida
AT510585B1 (de) 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
AU2014265483B2 (en) * 2013-05-14 2018-08-02 Biocryst Pharmaceuticals, Inc. Anti-influenza compositions and methods
CN104447585B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 吡嗪类化合物及其组合物及用途
CN104447583B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447584B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104402833B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104496918B (zh) * 2014-12-10 2016-08-24 广东东阳光药业有限公司 吡嗪衍生物及其用途
CN104817511B (zh) * 2015-04-27 2017-04-19 济南大学 一种丁烯二酸酐制备法匹拉韦关键中间体的方法
HK1254961A1 (en) * 2015-12-15 2019-08-02 Shionogi & Co., Ltd. Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
WO2020138067A1 (ja) 2018-12-25 2020-07-02 富士フイルム富山化学株式会社 ピラジン誘導体と細胞内におけるピラジン誘導体リボース三リン酸体の量を増加させる化合物とを組み合わせてなるrnaウイルス感染症治療剤
EP4144353A4 (en) * 2020-04-30 2024-08-28 FUJIFILM Toyama Chemical Co., Ltd. THERAPEUTIC AGENT AGAINST CORONAVIRUS INFECTION FORMED BY COMBINATION OF A PYRAZINE DERIVATIVE AND ANOTHER THERAPEUTIC DRUG AGAINST CORONAVIRUS INFECTION
US20230201238A1 (en) 2020-05-27 2023-06-29 Fujifilm Toyama Chemical Co., Ltd. Therapeutic agent for an rna virus infection comprising a combination of a pyrazine derivative and a thiopurine derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01197437A (ja) 1988-01-29 1989-08-09 Dso Pharmachim 抗ウイルス薬
DK1112743T3 (da) * 1998-08-20 2007-11-26 Toyama Chemical Co Ltd Nitrogenholdige heterocykliske carboxamidderivater eller salte deraf som antivirale midler
CA2456292A1 (en) 2001-08-14 2003-02-27 Toyama Chemical Co., Ltd. Novel virus growth inhibitor and/or virucidal method, and novel pyrazine nucleotide or pirazine nucleoside analog
JP2005354833A (ja) * 2004-06-11 2005-12-22 Fujinon Corp アクチュエータ
JP4689989B2 (ja) * 2004-08-27 2011-06-01 オリンパス株式会社 振動波リニアモータ及びそれを用いたレンズ装置
DE102008031715A1 (de) 2008-07-04 2010-01-07 Henkel Ag & Co. Kgaa Haarkonditionierende Mittel mit Imidazolinen

Also Published As

Publication number Publication date
RU2463051C2 (ru) 2012-10-10
CN101610772A (zh) 2009-12-23
HRP20130111T1 (hr) 2013-02-28
JP5255456B2 (ja) 2013-08-07
CN101610772B (zh) 2013-01-16
BRPI0807597B8 (pt) 2021-05-25
CA2677905C (en) 2015-03-24
EP2123276A4 (en) 2011-05-18
BRPI0807597A2 (pt) 2014-05-06
KR101479083B1 (ko) 2015-01-07
US20100087447A1 (en) 2010-04-08
CA2677905A1 (en) 2008-08-21
EP2123276B1 (en) 2012-11-28
AU2008215397A1 (en) 2008-08-21
IL200285A0 (en) 2010-04-29
JPWO2008099874A1 (ja) 2010-05-27
WO2008099874A1 (ja) 2008-08-21
US8759354B2 (en) 2014-06-24
PL2123276T3 (pl) 2013-04-30
SI2123276T1 (sl) 2013-03-29
EP2123276A1 (en) 2009-11-25
KR20090121289A (ko) 2009-11-25
BRPI0807597B1 (pt) 2021-03-02
MX2009008779A (es) 2009-11-05
NZ578989A (en) 2011-07-29
RU2009134516A (ru) 2011-03-27
AU2008215397B2 (en) 2012-09-06
PT2123276E (pt) 2013-01-16
ES2396595T3 (es) 2013-02-22
CY1113435T1 (el) 2016-06-22
ZA200905536B (en) 2010-10-27
IL200285A (en) 2014-06-30

Similar Documents

Publication Publication Date Title
DK2091599T3 (da) Forbedringer af og vedrørende drivmekanismer, der er egnet til anvendelse i anordninger til lægemiddelfremføring
DK3345625T3 (da) Farmaceutisk sammensætning og indgivelser deraf
DK2114924T3 (da) Co-krystaller og farmaceutiske sammensætninger omfattende disse
DK2471807T3 (da) Langtids-virkende polypeptider og fremgangsmåder til produktion og administration af samme
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
DK2346552T4 (da) Lægemiddelafgivelsesanordning og fremgangsmåde til fremstilling af en lægemiddelafgivelsesanordning
DK2379136T3 (da) Låsemekanisme til en lægemiddelfremføringsanordning og lægemiddelfremføringsanordning
DK2224893T3 (da) Forbedringer af og i relation til en madningsanordning
DK2046362T3 (da) Formulering omfattende valleprotein og hydrolysater til forbedring af muskelrekuperation
DK2334378T3 (da) Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
DK2001611T3 (da) Fremgangsmåde og sammensætning til oprensning af jord
DK2310073T3 (da) Lægemiddelafgivelsesanordning og fremgangsmåde til samling af en lægemiddelafgivelsesanordning
DK2173407T3 (da) Anordning til indgivelse af lægemiddel
DK2253644T3 (da) Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
DK2135603T3 (da) Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
DK1884242T3 (da) Farmaceutisk sammensætning omfattende lurasidon
DK2229360T3 (da) Indolinonderivater og fremgangsmåde til deres fremstilling
ATE493119T1 (de) Pharmazeutische zusammensetzung
DK2207773T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning deraf.
DK2180882T3 (da) Farmaceutisk faststofsammensætning af matrix-type
ZA200905536B (en) Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination
DK2313404T3 (da) Quinuclidin-carbonat-derivater og medicinsk sammensætning deraf
DK2222314T3 (da) Anvendelser og midler til opnåelse af bronchorelaxation
DK2475649T3 (da) Indenonderivat og farmaceutisk sammensætning omfattende samme
DK2158199T3 (da) Piperidinforbindelser og anvendelser deraf